UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Médecine et maladies infectieuses, ISSN 0399-077X, 06/2019, Volume 49, Issue 4, pp. S56 - S56
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 09/2018, Volume 320, Issue 10, pp. 984 - 994
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Escherichia coli Infections - mortality | Klebsiella pneumoniae - drug effects | Escherichia coli - drug effects | Humans | Middle Aged | Drug Resistance, Bacterial | Bacteremia - mortality | Ceftriaxone - pharmacology | Male | Cause of Death | Anti-Bacterial Agents - therapeutic use | Penicillanic Acid - therapeutic use | Adult | Female | Anti-Bacterial Agents - adverse effects | Meropenem | Penicillanic Acid - adverse effects | Thienamycins - adverse effects | Penicillanic Acid - analogs & derivatives | Thienamycins - therapeutic use | Escherichia coli Infections - drug therapy | Klebsiella Infections - drug therapy | Piperacillin, Tazobactam Drug Combination | Bacteremia - drug therapy | Piperacillin - adverse effects | Klebsiella Infections - mortality | Aged | Anti-Bacterial Agents - pharmacology | Piperacillin - therapeutic use | Klebsiella | Treatment outcome | Safety and security measures | Tazobactam | Escherichia coli | Patient outcomes | Analysis | Comparative analysis | Risk factors | Bacterial infections | Intravenous administration | Mortality | Clinical trials | Piperacillin-tazobactam | Infections | Ceftriaxone | Drug resistance | Patients | Side effects | Cephalosporins | E coli | Piperacillin | Drug therapy | Blood diseases | Blood culture | Carbapenems | Index Medicus | Abridged Index Medicus | Original Investigation | Research
Journal Article
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 03/2020, Volume 64, Issue 3
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Prospective Studies | Humans | Middle Aged | beta-Lactamase Inhibitors - blood | Critical Illness | Piperacillin, Tazobactam Drug Combination - pharmacokinetics | Male | beta-Lactamase Inhibitors - pharmacokinetics | Piperacillin, Tazobactam Drug Combination - blood | Tazobactam - blood | Tazobactam - pharmacokinetics | Female | Aged | Index Medicus
Journal Article
Expert review of anti-infective therapy, ISSN 1478-7210, 04/2018, Volume 16, Issue 4, pp. 307 - 320
tazobactam | ESBL | MDR | Antimicrobial resistance | ceftolozane | Pseudomonas | carbapenem-sparing | Enterobacteriaceae | Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Off-Label Use | Pseudomonas aeruginosa - isolation & purification | Intraabdominal Infections - microbiology | Pseudomonas Infections - drug therapy | Enterobacteriaceae Infections - microbiology | Humans | Tazobactam - pharmacology | Enterobacteriaceae - isolation & purification | Cephalosporins - administration & dosage | Pseudomonas aeruginosa - drug effects | Pseudomonas Infections - microbiology | Urinary Tract Infections - drug therapy | Tazobactam - administration & dosage | Drug Resistance, Multiple, Bacterial | Enterobacteriaceae - drug effects | Urinary Tract Infections - microbiology | Anti-Bacterial Agents - pharmacology | Anti-Bacterial Agents - administration & dosage | Cephalosporins - pharmacology | Intraabdominal Infections - drug therapy | Enterobacteriaceae Infections - drug therapy | Index Medicus
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 02/2020, Volume 21, Issue 3, p. 1026
Biochemistry & Molecular Biology | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Index Medicus | ceftazidime/avibactam (cza) | pseudomonas aeruginosa | piperacillin/tazobactam (p/t) | epigenetic profiling | antimicrobial resistance | ceftolozane/tazobactam (c/t) | rna sequencing (rnaseq) | whole-genome sequencing (wgs)
Journal Article
European journal of clinical microbiology & infectious diseases, ISSN 0934-9723, 8/2019, Volume 38, Issue 8, pp. 1457 - 1461
Medical Microbiology | Biomedicine | Ceftolozane/tazobactam | Internal Medicine | Pseudomonas aeruginosa | Multidrug resistant | Pharmacokinetic/pharmacodynamic | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Prospective Studies | Drug Administration Schedule | Pseudomonas Infections - drug therapy | Humans | Middle Aged | Male | Pseudomonas aeruginosa - drug effects | Infusions, Intravenous - methods | Cephalosporins - therapeutic use | Microbial Sensitivity Tests | Tazobactam - pharmacokinetics | Anti-Bacterial Agents - therapeutic use | Tazobactam - therapeutic use | Drug Resistance, Multiple, Bacterial | Anti-Bacterial Agents - pharmacokinetics | Adult | Cephalosporins - pharmacokinetics | Female | Drug resistance in microorganisms | Mortality | Antimicrobial activity | Intravenous administration | Infections | Pharmacology | Drug resistance | Patients | Respiratory tract | Time dependence | Infusion | Tazobactam | Minimum inhibitory concentration | Respiratory tract diseases | Intravenous infusion | Index Medicus
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 2017, Volume 64, Issue 5, pp. 666 - 674
Piperacillin-tazobactam | Vancomycin | Nephrotoxicity | Acute kidney injury | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Complications and side effects | Tazobactam | Piperacillin | Acute renal failure | Risk factors | Bacteria | Medical treatment | Kidney diseases
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 07/2016, Volume 63, Issue 2, pp. 234 - 241
ceftazidime/avibactam | ceftolozane/tazobactam | multidrug resistance | Pseudomonas | Enterobacteriaceae | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Azabicyclo Compounds - administration & dosage | Humans | Ceftazidime - administration & dosage | Cephalosporins - pharmacokinetics | beta-Lactamase Inhibitors - administration & dosage | Azabicyclo Compounds - pharmacokinetics | Cephalosporins - administration & dosage | Drug Therapy, Combination | beta-Lactamase Inhibitors - pharmacokinetics | Ceftazidime - pharmacokinetics | Care and treatment | Pneumonia | Enterobacter | Antibiotics | Analysis | Bacterial pneumonia | Clinical trials | Dosage and administration | Research | Index Medicus | ceftazidime | tazobactam | Invited | avibactam | ceftolozane
Journal Article
International journal of antimicrobial agents, ISSN 0924-8579, 03/2019, Volume 53, Issue 3, pp. 343 - 346
Gram-negative bacteraemia | Nephrotoxicity | Piperacillin/tazobactam | Acute kidney injury | Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Humans | Middle Aged | Bacteremia - drug therapy | Gram-Negative Bacterial Infections - drug therapy | Male | beta-Lactamase Inhibitors - administration & dosage | Piperacillin, Tazobactam Drug Combination - adverse effects | Incidence | beta-Lactamase Inhibitors - adverse effects | Aged, 80 and over | Female | Acute Kidney Injury - chemically induced | Aged | Anti-Bacterial Agents - adverse effects | Retrospective Studies | Anti-Bacterial Agents - administration & dosage | Piperacillin, Tazobactam Drug Combination - administration & dosage | Tazobactam | Analysis | Escherichia coli
Journal Article
10.
Full Text
Paraostéoarthropathie neurogène : une cause rare de fièvre prolongée chez le paraplégique
La revue de medecine interne, ISSN 0248-8663, 06/2019, Volume 40, pp. A210 - A211
Journal Article
La revue de medecine interne, ISSN 0248-8663, 06/2019, Volume 40, pp. A119 - A119
Journal Article
Journal of antimicrobial chemotherapy, ISSN 0305-7453, 01/2016, Volume 71, Issue 1, pp. 196 - 207
Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Intensive Care Units | Prospective Studies | Thienamycins - administration & dosage | Blood Chemical Analysis | Humans | Middle Aged | Thienamycins - pharmacokinetics | Critical Illness | Piperacillin - pharmacokinetics | Male | Treatment Outcome | Microbial Sensitivity Tests | Piperacillin - administration & dosage | Anti-Bacterial Agents - pharmacokinetics | Penicillanic Acid - pharmacokinetics | Female | Aged | Infusions, Intravenous | Anti-Bacterial Agents - administration & dosage | Penicillanic Acid - analogs & derivatives | Penicillanic Acid - administration & dosage | Intensive care | Pharmacology | Kinetics | Antibiotics | Patients | Clinical outcomes | Index Medicus | Life Sciences | Microbiology and Parasitology | Human health and pathology | Infectious diseases | Pharmaceutical sciences
Journal Article